Sangamo Therapeutics Inc (SGMO) Noticias

SGMO...$2.87...🥳Looking for the $3 Breakout...Last run from .30 to $3...

georgie18

Member Level
Re: None

Friday, December 13, 2024 9:33:14 AM

Post#
980
of 984
SGMO...$2.11...Starting up again...🥳

sgmo...............https://stockcharts.com/h-sc/ui?s=sgmo&p=W&b=5&g=0&id=p86431144783

Something going on. Up again. $2.72. Up 3%.

SGMO...$2.66...🥳...on the Breakout...

SGMO...$2.50...🥳...Trying for Upper Bollie Breakout here...

SGMO...$2.11...Starting up again...🥳

Career site shows just 2 temporary positions for weeks?
Maybe has momo till december 9 presentation of the ph3 in HEM A with Pfizer.

May go to 4 first but valuation makes no sense - overbought zinc finger dud.
Smart and extensive promotion campaign by management.

SGMO - Nice day and the start of another uptrend

SGMO...........................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
BUSINESS WIRE 4:15 PM ET 11/19/2024

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
BENZINGA 1:20 PM ET 11/14/2024

sgmo.............................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783

$SGMO > So-So earnings report brings out the sharks ...

Where will it settle ???

SGMO...$2.33...🥳...https://ih.advfn.com/stock-market/NASDAQ/sangamo-therapeutics-SGMO/stock-news/94894589/form-s-3-registration-statement-under-securities

SGMO...$2.53...Fins after close...🥳

georgie18

Member Level
Re: georgie18 post# 664188

Friday, November 08, 2024 11:09:45 AM

Post#
664225
of 664553
SGMO...$3.10s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 385366

Friday, November 08, 2024 9:21:06 AM

Post#
385382
of 385395
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...

georgie18

Member Level
Re: georgie18 post# 663989

Thursday, November 07, 2024 2:23:36 PM

Post#
664113
of 664186
SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

Have a Great Weekend Y'all...🥳

$SGMO earnings 11/12 . After market closes . 🚀🔥🏃💲

Enjoy the holiday weekend . >> M

SGMO...$3.10s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 385366

Friday, November 08, 2024 9:21:06 AM

Post#
385382
of 385395
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...

georgie18

Member Level
Re: georgie18 post# 663989

Thursday, November 07, 2024 2:23:36 PM

Post#
664113
of 664186
SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...

georgie18

Member Level
Re: georgie18 post# 663989

Thursday, November 07, 2024 2:23:36 PM

Post#
664113
of 664186
SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

Another great day 😃

$SGMO

SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

$SGMO at $2.33 is in BEAST mode > 🦍🚀🔥💲

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

Nice! 😃

$SGMO

SGMO......................................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783

SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

they keep wacking the 2 dollars.. please sell and get out of the way thank you

SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

Your statement implies we have ANY effect on how either SGMO or OMGA are trading. We dont.

The companies arent related at all. SGMO is zinc fingers and OMGA is oncology and obesity.
OMGA has Novo Nordisk, SGMO has Genentech. SGMO trades at ~9x the market cap of OMGA. Its not a secret that sometimes theres a bidding war around assets or entire companies. That means if a company is desirable, the bidder with the deepest pockets will come out on top.

Ponken, Bashing this to help your OMGA Investment?? LOL...

OMGA is years away & anything mRNA based is tented with serious safety issues imo

a lot of momentum here..... I believe too much.
Sitting at 400m market cap, ~1 quarter left in cash and 150m operating expense per year

SGMO Upcoming Quarter's Earnings >>> Maybe . ( I know , we wait )
Announce Date
11/8/2024 (Post-Market)

Says Seeking Alpha : https://seekingalpha.com/symbol/SGMO/earnings

Agree Molee! Have a great weekend 😃

$SGMO

$SGMO has held up remarkably well considering all the shorts / sharks in the waters .

Enjoy the weekend team >> M

According to TD Its Friday, 1st Nov..??

CC at 4:30 AM
Earning at 9:30 AM

Thanks . Fidelity shows today , but that's not always correct .

No - they will announce when they will announce earnings. They have not yet made the Q3 announcement. Probably wrapping up something first.

I think earnings report is due out today / soon ?

jondoeuk,

Is the company you representing have been shorting SGMO???

hummmmm

Good morning and thank you jondoeuk. Many of these types of companies struggle at first, but when they have a 'hit', things can turn around quickly. We'll have to wait and see IMHO.
Unless they upgrade their tech to include additional tools
News Release:

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

October 22, 2024

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

RICHMOND, Calif.--(BUSINESS WIRE)--Oct. 22, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the outcome of a recent successful interaction with the U.S. FDA, providing a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec, or ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease...

https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-alignment-fda-accelerated

$SGMO

Pioneering the future of genomic medicine? The company was founded in 1995. Gene editing has evolved. Unless they upgrade their tech to include additional tools I can't seem them being a meaningful player in any way. Too many failures* in their long history. Another issue is the management.

* This includes diabetic neuropathy, HIV, IVPRP, TDT/SCD, oncology (with GILD), and CNS (with BIIB and NVS). Investments in CAR-Tregs (and elsewhere) were written off. Also, programs in Huntington's, ALS, and others that still have not gotten off the ground. They were touting base editing at one point. But not to worry, they pivoted again!

SGMO...............................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783

Still very good volume .. Higher highs and higher lows ...

Thanks...🥳

Good morning SGMO-ers.
This spider has been busy for some more low-flying shares... waiting and watching 😃

$SGMO

Nice call of $2 break a while back ...

Always happy to have a chartist on board ...